Panacea Biotec shares gifted to Rajesh Jain HUF; 200,000 shares (0.09%) transferred

What Panacea Biotec announced

On 13 July 2026 the Bombay Stock Exchange received a disclosure from Panacea Biotec Ltd (BSE: 531349) under Regulation 10(7) of the SEBI Substantial Acquisition of Shares & Takeovers (SAST) Regulations, 2011. The filing details a promoter‑group transaction in which Rajesh Jain HUF acquired 200,000 equity shares of the company from Dr Rajesh Jain on 12 June 2026. The shares were transferred by way of gift, i.e., without any monetary consideration, and the post‑transaction holding of the HUF stands at 0.09 % of Panacea Biotec’s total share capital.

Details of the acquisition

• Acquirer: Rajesh Jain HUF (promoter group of Panacea Biotec) – PAN AABHR5243M, address 18 by 56, East Park Area, Karol Bagh, New Delhi.
• Seller: Dr Rajesh Jain, Karta of the HUF and promoter of the target company.
• Date of acquisition: 12 June 2026.
• Number of shares transferred: 200,000 shares.
• Shareholding before acquisition: 0 shares for the HUF (0 %); 30,217,312 shares for the seller (13.57 %).
• Shareholding after acquisition: 200,000 shares for the HUF (0.09 %); 30,017,312 shares for the seller (13.48 %).
• Consideration: None – the transfer was a gift.
• Relationship: The seller is the Karta of the acquiring HUF and both belong to the promoters and promoters’ group of Panacea Biotec.
• Regulatory trigger: The post‑acquisition holding of 0.09 % is well below the 1 % threshold that would normally invoke a mandatory open‑offer, allowing the transaction to be treated under the general exemption of Regulation 10.1(a)(ii).

Regulatory compliance and exemptions

The filing confirms that all procedural requirements under the SAST framework were satisfied:

• A report to SEBI was filed on 5 June 2026, within 21 working days of the acquisition, together with the requisite fee.
• Notice to the stock exchanges (NSE and BSE) was given on 15 June 2026, at least four working days before the acquisition date, as required by Regulation 10(5).
• The VWAP of Panacea Biotec shares for the preceding 60 trading days was Rs 387.37, and the share price was not more than 25 % above this VWAP, satisfying the price‑test exemption.
• The transaction is exempt from the valuation report under Regulation 8.2(d) and (e) because it falls under the general exemption provided in Regulation 10.1(a)(ii).
• Both acquirer and seller are listed as promoters in the company’s shareholding pattern, satisfying the disclosure requirement.

Key facts at a glance

Why this matters for investors

The transaction does not alter the control dynamics of Panacea Biotec, as the acquirer’s stake remains well below the 1 % threshold that would trigger a mandatory open‑offer or require additional disclosures about influence. However, the filing is material from a compliance perspective because it demonstrates that the promoters are adhering to SEBI’s takeover rules, filing all required reports and fees on time. The reduction in the promoter’s shareholding (from 13.57 % to 13.48 %) is marginal and unlikely to affect voting power or dividend entitlements. Investors should note that the gift‑type transfer is permissible under the exemption framework, and no dilution of existing shareholders occurs because no new shares were issued.

Conclusion

Panacea Biotec Ltd disclosed that its promoter‑group entity, Rajesh Jain HUF, received 200,000 shares as a gift from Dr Rajesh Jain on 12 June 2026, raising its holding to 0.09 % of the company. The transaction complies with all SEBI SAST requirements, qualifying for a general exemption and involving no cash consideration. While the share‑holding percentages of both parties changed only slightly, the filing confirms regulatory adherence and completes the required disclosures. No further approvals or actions are pending under the SAST regime for this specific transfer.